A two-gene methylation signature for the diagnosis of bladder cancer in urine. (1st February 2019)

• Record Type: Journal Article
• Authors: Bosschieter, Judith; Nieuwenhuijzen, Jakko A; Hentschel, Anouk; van Splunter, Annina P; Segerink, Loes I; Vis, André N; Wilting, Saskia M; Lissenberg-Witte, Birgit I; A van Moorselaar, R Jeroen; Steenbergen, Renske DM
• Is Part Of: Epigenomics. Volume 11:Number 3(2019)
• Page Start: 337
• Page End: 347
• Publication Date: 2019-02-01
• Subjects: biomarkers -- methylation -- molecular diagnostics -- urinary bladder neoplasms -- urine analysis; Epigenesis -- Periodicals; Genomics -- Periodicals; Chromatin -- Periodicals; DNA -- Periodicals; 572.87
• DOI: 10.2217/epi-2018-0094
• Languages: English
• ISSNs: 1750-1911

Abstract

Aim: To analyze the potential of 14 cancer-associated genes, including six miRNAs, for bladder cancer (BC) diagnosis in urine.Patients & methods: DNA methylation levels of 14 genes were analyzed in urine of 72 BC patients and 75 healthy controls using quantitative methylation-specific PCR. Multivariate logistic regression analysis was used to determine an optimal marker panel.Results: Ten genes were significantly hypermethylated in BC patients. The GHSR/MAL combination showed the best diagnostic performance, reaching a sensitivity of 92% (95% CI: 86–99) and a specificity of 85% (95% CI: 76–94).Conclusion: We identified a novel two-gene panel with a high diagnostic accuracy for BC that can be applied in a noninvasive, urine-based test.